Cyclacel Pharmaceuticals (CYCC) Competitors $0.34 -0.01 (-1.73%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.34 +0.00 (+0.59%) As of 02/21/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CYCC vs. EDSA, PBM, BFRI, AYTU, CYCN, CELZ, AIM, DWTX, INDP, and NLSPShould you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include Edesa Biotech (EDSA), Psyence Biomedical (PBM), Biofrontera (BFRI), Aytu BioPharma (AYTU), Cyclerion Therapeutics (CYCN), Creative Medical Technology (CELZ), AIM ImmunoTech (AIM), Dogwood Therapeutics (DWTX), Indaptus Therapeutics (INDP), and NLS Pharmaceutics (NLSP). These companies are all part of the "pharmaceutical products" industry. Cyclacel Pharmaceuticals vs. Edesa Biotech Psyence Biomedical Biofrontera Aytu BioPharma Cyclerion Therapeutics Creative Medical Technology AIM ImmunoTech Dogwood Therapeutics Indaptus Therapeutics NLS Pharmaceutics Cyclacel Pharmaceuticals (NASDAQ:CYCC) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability. Does the MarketBeat Community prefer CYCC or EDSA? Cyclacel Pharmaceuticals received 160 more outperform votes than Edesa Biotech when rated by MarketBeat users. However, 77.14% of users gave Edesa Biotech an outperform vote while only 45.95% of users gave Cyclacel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCyclacel PharmaceuticalsOutperform Votes18745.95% Underperform Votes22054.05% Edesa BiotechOutperform Votes2777.14% Underperform Votes822.86% Which has better earnings & valuation, CYCC or EDSA? Edesa Biotech has lower revenue, but higher earnings than Cyclacel Pharmaceuticals. Edesa Biotech is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclacel Pharmaceuticals$420K5.09-$22.56M-$9.40-0.04Edesa BiotechN/AN/A-$6.17M-$1.87-1.27 Which has more risk and volatility, CYCC or EDSA? Cyclacel Pharmaceuticals has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Do institutionals & insiders have more ownership in CYCC or EDSA? 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 24.0% of Cyclacel Pharmaceuticals shares are owned by insiders. Comparatively, 25.0% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is CYCC or EDSA more profitable? Edesa Biotech has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -18,150.00%. Edesa Biotech's return on equity of -233.69% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cyclacel Pharmaceuticals-18,150.00% -1,901.11% -188.23% Edesa Biotech N/A -233.69%-124.14% Do analysts rate CYCC or EDSA? Cyclacel Pharmaceuticals currently has a consensus price target of $11.00, indicating a potential upside of 3,135.29%. Edesa Biotech has a consensus price target of $21.00, indicating a potential upside of 782.35%. Given Cyclacel Pharmaceuticals' higher possible upside, equities research analysts clearly believe Cyclacel Pharmaceuticals is more favorable than Edesa Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer CYCC or EDSA? In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 1 mentions for Cyclacel Pharmaceuticals and 0 mentions for Edesa Biotech. Cyclacel Pharmaceuticals' average media sentiment score of 0.00 beat Edesa Biotech's score of -0.02 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Cyclacel Pharmaceuticals Neutral Edesa Biotech Neutral SummaryEdesa Biotech beats Cyclacel Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCC vs. The Competition Export to ExcelMetricCyclacel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.18M$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.045.4725.4719.00Price / Sales5.09306.08447.5876.30Price / CashN/A65.6738.0134.83Price / Book0.606.717.644.62Net Income-$22.56M$138.33M$3.18B$245.85M7 Day Performance-8.53%-2.61%-1.99%-2.68%1 Month Performance-3.74%-2.32%-0.42%-2.19%1 Year Performance-86.97%-5.31%16.51%12.84% Cyclacel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCCCyclacel Pharmaceuticals2.5466 of 5 stars$0.34-1.7%$11.00+3,135.3%-87.5%$2.18M$420,000.00-0.0414Analyst ForecastNews CoverageEDSAEdesa Biotech2.6638 of 5 stars$2.69-17.2%$21.00+680.7%-53.9%$9.33MN/A-1.3920Earnings ReportHigh Trading VolumePBMPsyence BiomedicalN/A$1.40+9.0%N/A-97.0%$9.21MN/A0.00N/APositive NewsBFRIBiofrontera2.6492 of 5 stars$1.18+0.9%$7.00+493.2%+13.6%$9.14M$35.36M-0.5270News CoverageAYTUAytu BioPharma1.0333 of 5 stars$1.39+0.4%N/A-55.0%$8.52M$81M-1.13160High Trading VolumeCYCNCyclerion Therapeutics0.7851 of 5 stars$3.12+3.0%N/A-1.1%$8.46M$1.62M0.0030CELZCreative Medical Technology0.8967 of 5 stars$4.74+3.3%N/A+28.0%$8.30M$10,000.00-1.255Gap DownHigh Trading VolumeAIMAIM ImmunoTech1.9945 of 5 stars$0.13-6.9%$2.75+2,031.8%-67.1%$8.23M$200,000.00-0.2720High Trading VolumeDWTXDogwood TherapeuticsN/A$6.13-8.6%N/AN/A$8.15MN/A-0.945Gap DownINDPIndaptus Therapeutics3.1124 of 5 stars$0.80+2.1%$8.50+963.8%-52.9%$8.15MN/A-0.476Gap UpNLSPNLS PharmaceuticsN/A$2.26-1.7%N/A+364.1%$8.14MN/A0.006Gap Up Related Companies and Tools Related Companies Edesa Biotech Competitors Psyence Biomedical Competitors Biofrontera Competitors Aytu BioPharma Competitors Cyclerion Therapeutics Competitors Creative Medical Technology Competitors AIM ImmunoTech Competitors Dogwood Therapeutics Competitors Indaptus Therapeutics Competitors NLS Pharmaceutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYCC) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYCC Stock Alerts